These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 23537724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E.
    Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.
    Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M.
    Blood; 2012 Sep 20; 120(12):2405-11. PubMed ID: 22859609
    [Abstract] [Full Text] [Related]

  • 7. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
    Martinowitz U, Lissitchkov T, Lubetsky A, Jotov G, Barazani-Brutman T, Voigt C, Jacobs I, Wuerfel T, Santagostino E.
    Haemophilia; 2015 Nov 20; 21(6):784-90. PubMed ID: 25990590
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Half-life extension through albumin fusion technologies.
    Schulte S.
    Thromb Res; 2009 Dec 20; 124 Suppl 2():S6-8. PubMed ID: 20109653
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López-Fernández MF, Mahlangu J, Pabinger I, Li Y, Wolko D, Voigt C, Jacobs I, Santagostino E.
    Haemophilia; 2016 Jul 20; 22(4):e259-66. PubMed ID: 27333467
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C, Marino R, Lambert C, Mangles S, Sommerer P, Rives V, Maro G, Malcangi G.
    Adv Ther; 2020 Jun 20; 37(6):2988-2998. PubMed ID: 32333327
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B.
    Mancuso ME, Lubetsky A, Pan-Petesch B, Lissitchkov T, Nagao A, Seifert W, Li Y, Santagostino E.
    J Thromb Haemost; 2020 May 20; 18(5):1065-1074. PubMed ID: 32078256
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S.
    Thromb Res; 2013 Mar 20; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.